The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

The drug Zepbound might not have the same name recognition as Ozempic, but it's another in the class to treat obesity and ...

Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...

A 2024 study in the American Journal of Managed Care found that patients’ health care costs declined by $7,502 after they began treatment with the anti-obesity drug semaglutide. Importantly ...

Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...